Prelude Total Assets vs Short Long Term Debt Total Analysis
| PRLD Stock | USD 0.76 0.01 1.33% |
Prelude Therapeutics financial indicator trend analysis is much more than just breaking down Prelude Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Prelude Therapeutics is a good investment. Please check the relationship between Prelude Therapeutics Total Assets and its Short Long Term Debt Total accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.
Total Assets vs Short Long Term Debt Total
Total Assets vs Short Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Prelude Therapeutics Total Assets account and Short Long Term Debt Total. At this time, the significance of the direction appears to have strong relationship.
The correlation between Prelude Therapeutics' Total Assets and Short Long Term Debt Total is 0.68. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Prelude Therapeutics, assuming nothing else is changed. The correlation between historical values of Prelude Therapeutics' Total Assets and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Prelude Therapeutics are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Total Assets i.e., Prelude Therapeutics' Total Assets and Short Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.68 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Total Assets
Total assets refers to the total amount of Prelude Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Prelude Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Short Long Term Debt Total
Most indicators from Prelude Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Prelude Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.As of March 1, 2025, Selling General Administrative is expected to decline to about 18.9 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 124.1 M
| 2022 | 2023 | 2024 | 2025 (projected) | Reconciled Depreciation | 1.3M | 1.2M | 1.4M | 827.2K | Total Operating Expenses | 123.5M | 132.3M | 152.1M | 86.4M |
Prelude Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Prelude Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Prelude Therapeutics fundamental ratios Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 223.6M | 305.1M | 220.5M | 277.7M | 319.3M | 195.3M | |
| Other Current Liab | 7.5M | 7.9M | 11.3M | 15.8M | 18.1M | 19.0M | |
| Total Current Liabilities | 11.4M | 19.2M | 21.7M | 21.8M | 25.1M | 14.9M | |
| Total Stockholder Equity | 212.2M | 285.9M | 195.4M | 237.1M | 272.7M | 157.4M | |
| Net Tangible Assets | (49.4M) | 212.2M | 285.9M | 195.4M | 224.8M | 136.7M | |
| Property Plant And Equipment Net | 2.5M | 5.6M | 6.7M | 37.7M | 43.4M | 45.6M | |
| Net Debt | (218.3M) | (30.1M) | (28.8M) | (8.4M) | (9.7M) | (10.1M) | |
| Retained Earnings | (107.4M) | (219.1M) | (334.6M) | (456.4M) | (410.8M) | (390.2M) | |
| Accounts Payable | 3.9M | 7.8M | 6.8M | 4.6M | 5.3M | 4.8M | |
| Cash | 218.3M | 31.8M | 30.6M | 25.3M | 22.8M | 45.4M | |
| Non Current Assets Total | 2.8M | 10.0M | 16.1M | 42.1M | 48.4M | 50.8M | |
| Cash And Short Term Investments | 218.3M | 291.2M | 201.7M | 232.9M | 267.9M | 179.4M | |
| Common Stock Shares Outstanding | 43.7M | 47.6M | 47.4M | 60.4M | 69.4M | 48.3M | |
| Liabilities And Stockholders Equity | 223.6M | 305.1M | 220.5M | 277.7M | 319.3M | 195.3M | |
| Non Current Liabilities Total | 32K | 9.6M | 3.4M | 18.7M | 16.9M | 18.0M | |
| Other Stockholder Equity | 96.0M | 505.7M | 531.7M | 693.3M | 797.2M | 837.1M | |
| Total Liab | 11.4M | 19.2M | 25.1M | 40.6M | 36.5M | 27.6M | |
| Net Invested Capital | 212.2M | 285.9M | 195.4M | 237.1M | 272.7M | 157.4M | |
| Property Plant And Equipment Gross | 2.5M | 5.6M | 6.7M | 41.3M | 47.5M | 49.9M | |
| Total Current Assets | 220.8M | 295.1M | 204.4M | 235.6M | 270.9M | 181.8M | |
| Accumulated Other Comprehensive Income | (223.6M) | (711K) | (1.7M) | 223K | 256.5K | 269.3K | |
| Non Current Liabilities Other | 5K | 32K | 3.4M | 3.3M | 3.8M | 4.0M | |
| Net Working Capital | 209.4M | 275.9M | 182.7M | 213.8M | 245.8M | 166.9M | |
| Property Plant Equipment | 1.6M | 2.5M | 5.6M | 6.7M | 7.7M | 8.1M | |
| Other Current Assets | 5M | 7.8M | 2.7M | 2.7M | 3.1M | 4.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.